Skip to main content

Advertisement

SpringerLink
Log in

Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

Our aim was to evaluate the efficacy and safety of S-1 in heavily pre-treated patients with advanced (FIGO stage IVB) or recurrent cervical cancer.

Methods

The Institutional Review Board of our hospital approved the protocol for this retrospective phase II study. Patients with measurable disease received two oral doses of S-1 (35 mg/m2) daily for 4 weeks of a 6-week cycle or 2 weeks of a 3-week cycle. The antitumor effect, time to progression, overall survival, and adverse events were investigated.

Results

We retrospectively analyzed relevant data of 28 patients with advanced or recurrent cervical cancer. Twenty-two patients had prior chemotherapy (not including chemoradiotherapy) and 27 had prior radiotherapy. The median number of prior chemotherapy regimens and cycles was 2 (range 0–4) and 7 (range 0–35), respectively. Two patients (7.1 %) had partial response, and 10 patients (35.7 %) had stable disease. Ten patients (35.7 %) discontinued the therapy because of progressive disease. The response in 5 patients could not be evaluated because of termination of treatment in the middle of the first cycle. The disease control rate was 42.8 %. After a median follow-up duration of 7.5 months, the median time to progression was 4.2 months (95 % CI 2.7–5.4) and the median overall survival was 9.92 months (95 % CI 9.20–NA). The two patients with partial response had received less prior chemotherapy.

Conclusions

Oral S-1 in palliative chemotherapy is a useful and well-tolerated treatment in heavily pre-treated patients with advanced or recurrent uterine cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani PCA (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108

  2. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150

  3. Center for Cancer control Information Services, ganjoho.jp. http://ganjoho.jp/. Accessed 2014 March 6

  4. Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, Lee SP, Hsueh S (2004) Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 60:249–257

    Article  PubMed  Google Scholar 

  5. Wang CJ, Lai CH, Huang HJ, Hong JH, Chou HH, Huang KG, Lin JD (1999) Recurrent cervical carcinoma after primary radical surgery. Am J Obstet Gynecol 181:518–524

    Article  PubMed  CAS  Google Scholar 

  6. Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R, Okuda H, Takahashi T, Origasa H, Sugimori H (2004) Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report. Int J Oncol 24:1175–1179

    PubMed  CAS  Google Scholar 

  7. Miura K, Shirasaka T, Yamaue H, Sasaki I (2012) S-1 as a core anticancer fluoropyrimidine agent. Expert Opin Drug Deliv 9(3):273–286

    Article  PubMed  CAS  Google Scholar 

  8. Katsumata N, Hirai Y, Kamiura S, Sugiyama T, Kokawa K, Hatae M, Nishimura R, Ochiai K (2011) Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol 22:1353–1357

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  9. Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, Tanigawa T, Yamamoto H, Kurokawa E (2003) A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer 6(Suppl 1):34–39

    Article  PubMed  Google Scholar 

  10. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, Sugita M (2005) Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 93:884–889

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Imamura H, Furukawa H, Kishimoto T, Nakae S, Inoue K, Tsukahara Y, Imano M, Yamazaki K, Okano S, Morimoto T, Sugihara S, Shimokawa T (2007) Phase II study of 2-week TS-1 administration followed by 1-week rest for gastric cancer. Hepatogastroenterology 54:2167–2171

    PubMed  CAS  Google Scholar 

  12. Hwang JH, Lim MC, Seo SS, Kang S, Park SY, Kim JY (2012) Outcomes and toxicities for the treatment of stage IVB cervical cancer. Arch Gynecol Obstet 285(6):1685–1693

    Article  PubMed  CAS  Google Scholar 

  13. Tian ZZ, Li S, Wang Y, Yue YJ, Zhu XH, Zhao R, Zhang CL, Wei SH (2014) Investigation of uterine arterial chemoembolization and uterine arterial infusion chemotherapy for advanced cervical cancer before radical radiotherapy: a long-term follow-up study. Arch Gynecol Obstet 290(1):155–162

    Article  PubMed  CAS  Google Scholar 

  14. Garcia AA, Blessing JA, Darcy KM, Lenz HJ, Zhang W, Hannigan E, Moore DH (2007) Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study. Gynecol Oncol 104:572–579

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  15. Look KY, Blessing JA, Gallup DG, Lentz SS (1996) A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 19:439–441

    Article  PubMed  CAS  Google Scholar 

  16. Schilder RJ, Blessing J, Cohn DE (2005) Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 96:103–107

    Article  PubMed  CAS  Google Scholar 

  17. Coleman RE, Harper PG, Gallagher C, Osborne R, Rankin EM, Silverstone AC et al (1986) A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 18:280–283

    Article  PubMed  CAS  Google Scholar 

  18. Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY (1993) Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 168:805–807

    Article  PubMed  CAS  Google Scholar 

  19. Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ (1997) Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol Off J Am Soc Clin Oncol 15:625–631

    CAS  Google Scholar 

  20. Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA (2000) Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 77:446–449

    Article  PubMed  CAS  Google Scholar 

  21. Muderspach LI, Blessing JA, Levenback C, Moore JL Jr (2001) A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 81:213–215

    Article  PubMed  CAS  Google Scholar 

  22. Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A (2004) Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 92:639–643

    Article  PubMed  CAS  Google Scholar 

  23. Takatori E, Shoji T, Suga Y, Niinuma H, Miura Y, Kaido Y, Takada A, Kagabu M, Takeuchi S, Sugiyama T (2014) A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy of patients with recurrent adenocarcinoma of the uterine cervix. Int J Clin Onclo 19(2):336–340

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology, Cancer Institute Hospital, 3-8-31 Ariake, Koutou-ku, Tokyo, 135-8550, Japan

    Terumi Tanigawa, Maki Matoda, Akiko Yamamoto, Hidetaka Nomura, Sanshiro Okamoto, Kimihiko Sakamoto, Eiji Kondo, Kohei Omatsu, Kazuyoshi Kato & Nobuhiro Takeshima

Authors
  1. Terumi Tanigawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maki Matoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akiko Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hidetaka Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sanshiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kimihiko Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eiji Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kohei Omatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuyoshi Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nobuhiro Takeshima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Terumi Tanigawa.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanigawa, T., Matoda, M., Yamamoto, A. et al. Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer. Arch Gynecol Obstet 293, 633–638 (2016). https://doi.org/10.1007/s00404-015-3866-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-015-3866-z

Keywords

Search

Navigation